Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma

Purpose Preclinical evidence suggests the importance of Janus activating kinase (JAK) and TANK-binding kinase 1 (TBK1) in pancreatic ductal adenocarcinoma (PDAC). We evaluated the safety and efficacy of momelotinib (MMB), a JAK1/2 inhibitor with additional activity against TBK1, plus albumin-bound p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Kimmie, Hendifar, Andrew, Starodub, Alexander, Chaves, Jorge, Yang, Yingsi, Koh, Brian, Barbie, David, Hahn, William C., Fuchs, Charles S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510909/
https://www.ncbi.nlm.nih.gov/pubmed/30105668
http://dx.doi.org/10.1007/s10637-018-0650-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510909/
https://www.ncbi.nlm.nih.gov/pubmed/30105668
http://dx.doi.org/10.1007/s10637-018-0650-5

Ejemplares similares